Zacks Investment Research Lowers Newron Pharmaceuticals (NWPHF) to Hold

Zacks Investment Research downgraded shares of Newron Pharmaceuticals (OTCMKTS:NWPHF) from a buy rating to a hold rating in a research note issued to investors on Wednesday, Zacks.com reports.

According to Zacks, “Newron Pharmaceuticals SpA is a biopharmaceutical company. It focuses on the discovery and development of drugs for the treatment of central nervous system disorders and pain primarily in Italy and internationally. Newron Pharmaceuticals SpA is headquartered in Bresso, Italy. “

Shares of Newron Pharmaceuticals stock opened at $9.25 on Wednesday. Newron Pharmaceuticals has a one year low of $7.98 and a one year high of $9.25.

About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system in Italy and internationally. The company offers Xadago (safinamide) for the treatment of Parkinson's disease.

See Also: Dividend Aristocrat Index

Get a free copy of the Zacks research report on Newron Pharmaceuticals (NWPHF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Newron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Newron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.